If Approved, FDA Drug Labeling Could Decide Success of Afrezza

The U.S. Food and Drug Administration’s (FDA) delay in completing its review of MannKind Corp.’s ultra rapid-acting insulin therapy, called Afrezza, by the expected action date of January 16 has added to uncertainty over the commercial prospects of this experimental inhaled insulin.
BNET